HKSE - Delayed Quote ? HKD Kintor Pharmaceutical Limited (9939.HK) Follow Compare 1.170 +0.010 (+0.86%) As of 9:53 AM GMT+8. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations GT20029 China Phase II Trial For AGA Reached Primary Endpoint Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the China phase II clinical trial (the "Phase II Clinical Trial") of its in-house developed first-in-class androgen receptor ("AR") proteolysis targeting chimera ("PROTAC") compound GT20029 tincture for the treatment of male androgenetic alopecia ("AGA") has reached the primary endpoint, with statistically significan PR Newswire ? 5 months ago KNTPF Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939.HK), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announces that Kintor and its cooperative partner had published an article named MYC Induces CDK4/6 Inhibitors Resistance by Promoting pRB1 Degradation in a subsidiary journal of Nature—Nature Communications (Impact factor: 16.6). Nature Communications is one of the top journals in biology field and is classified as Q1 in several PR Newswire ? 7 months ago KNTPF Performance Overview Trailing total returns as of 10/23/2024, which may include dividends or other distributions. Benchmark is HANG SENG INDEX Return 9939.HK HANG SENG INDEX YTD -28.22% +21.45% 1-Year -53.39% +20.57% 3-Year -97.31% -20.76%
